Key Highlights
- 95 percent of Humana (NYSE:HUM) Medicare Advantage members are in plans rated 4 stars or above for 2027, the company said on about October 9, and shares jumped roughly 12 to 15 percent in published market data. The close on October 15 was USD 432.20.
- USD 298.81 was the October 15 close for Cigna Group (NYSE:CI), up 3.19 percent and about 4.0 percent below the 52-week high of USD 311.34, simple arithmetic. At its September 30 investor day it reportedly set a USD 45 EPS floor.
- October 27, 2026 is when HCA Healthcare (NYSE:HCA) holds its third quarter call at 10:00 a.m. ET. The stock closed at USD 468.50 on October 15, down 0.41 percent and about 15.8 percent below the 52-week high of USD 556.52, simple arithmetic.
- USD 315 million is the reported amount CVS Health (NYSE:CVS) agreed to pay to resolve a Justice Department opioid prescription lawsuit on about October 14. Aetna said over 69 percent of members are in 2027 plans rated 4 stars or higher.
Humana (NYSE:HUM)
Star Ratings are the federal quality scores that decide whether Medicare Advantage plans earn bonus payments, so a better score feeds directly into revenue. The company said 95 percent of its members are in plans rated 4 stars or above for 2027, and the stock reacted with a jump of roughly 12 to 15 percent around October 9 and 10. Baird upgraded to Buy, Raymond James upgraded to Outperform with a USD 520 target, and Oppenheimer raised its target to USD 525 from USD 475. On about October 14 the company announced a joint venture with funds managed by HPS Investment Partners, part of BlackRock, to manage CenterWell senior primary care clinics, and the financial terms were not verified. Humana (NYSE:HUM) closed at USD 432.20, about 5.3 percent below its 52-week high of USD 456.50, simple arithmetic, for a market value near USD 51.9 billion. The risk is that the re-rating already prices the ratings win, while medical cost trend remains unproven and the joint venture terms are undisclosed. Results come November 6, 2026.
Cigna Group (NYSE:CI)
Cigna rose 3.19 percent on October 15, 2026 to USD 298.81, for a market value near USD 78.96 billion and a 52-week range of USD 239.51 to USD 311.34. No company release explains that day's move, which fits a sector rally after the Humana news. The story is the September 30 investor day, where the company introduced its Lead to One strategy, reportedly a USD 45 EPS floor and a USD 3 billion workflow modernization and productivity program. A floor is a minimum earnings target, so it is a company goal, not a guarantee. Cigna Group (NYSE:CI) raised its annual profit forecast with second quarter results on July 30, and Piper Sandler lifted its target to USD 370 from USD 346 with an Overweight rating. Evercore ISI is more cautious, initiating at In Line with a USD 290 target on September 11. The risks are execution on the productivity plan, pharmacy benefit regulation and a stock already close to its high. Results come November 5, 2026.
HCA Healthcare (NYSE:HCA)
HCA is the pure hospital operator in this group, so its earnings depend on admissions, payer mix and the rates insurers agree to pay. That puts it on the opposite side of the table from Humana, because a stronger insurer margin can mean tougher rate talks. The stock closed at USD 468.50 on October 15, 2026, down 0.41 percent, with a market value near USD 101.4 billion and a 52-week range of USD 353.99 to USD 556.52. RBC raised its target to USD 496 from USD 435 around October 8, TD Cowen lifted its target to USD 460 from USD 431 around October 13, and BMO initiated at Outperform with a USD 495 target on about September 22. HCA Healthcare (NYSE:HCA) completed its purchase of The College of Health Care Professions on about September 15. The risk is a volume or payer-mix surprise on October 27, 2026, the first report in this group, with the call at 10:00 a.m. ET.
CVS Health (NYSE:CVS)
CVS rose 2.42 percent to USD 92.58 on October 15, 2026, in a 52-week range of USD 69.51 to USD 110.68, about 16.4 percent below the high (simple arithmetic). It is the Star Ratings laggard: Aetna said over 69 percent of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, against Humana's 95 percent, and its plans reportedly lost ground in the federal ratings. The company also agreed to pay USD 315 million to resolve a Justice Department opioid prescription lawsuit, a one-time cost that does not change operations. Leerink cut its target to USD 112 from USD 119 and kept an Outperform rating on October 13. CVS Health (NYSE:CVS) pays USD 2.66 a share, a 2.87 percent yield, with an ex-dividend date of October 22. The risk is slower recovery in Medicare Advantage margins, because lower ratings mean smaller bonus payments, and further legal costs. Results come November 4, 2026.
Where Things Stand
It depends, and on the evidence Humana (NYSE:HUM) has the strongest near-term momentum, because 95 percent of its members sit in 4-star plans and analysts raised targets. That is already in the price, up roughly 12 to 15 percent in a day. Cigna Group (NYSE:CI) offers a plan and an EPS floor. HCA Healthcare (NYSE:HCA) offers a hospital counterweight reporting first on October 27. CVS Health (NYSE:CVS) trades about 16.4 percent below its high with weaker ratings. The first test is HCA on October 27, then CVS on November 4, Cigna on November 5 and Humana on November 6, 2026.






Please wait processing your request...